TDF-Based HIV PrEP Use During Pregnancy May Not Raise Risk Of Adverse Outcomes Compared To Placebo, Review Finds

Infectious Disease Advisor (7/1, Lee) reports an analysis of four trials evaluating the safety of “tenofovir disoproxil fumarate (TDF)-based HIV pre-exposure prophylaxis (PrEP) use during pregnancy” – the Partners PrEP Study, TDF2 Study, FEM-PrEP, and VOI...